Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell

Wonchung Lim1, Chounghun Kang2

  • 1Department of Sports Medicine, College of Health Science, Cheongju University, Cheongju, South Korea.

Insights

Avenanthramide C (AVC) from oats reduces inflammation. This study shows AVC inhibits hypoxia-induced cyclooxygenase-2 (COX-2) via SIRT1 activation, suggesting benefits for lung inflammation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Avenanthramide C (AVC), a compound found in oats, exhibits anti-inflammatory properties.
  • Hypoxia can induce cyclooxygenase-2 (COX-2) expression, contributing to inflammation.
  • Understanding the molecular mechanisms regulating COX-2 under hypoxia is crucial for developing anti-inflammatory strategies.

Purpose of the Study:

  • To investigate the effect of Avenanthramide C (AVC) on hypoxia-induced cyclooxygenase-2 (COX-2) expression in A549 lung cells.
  • To elucidate the role of SIRT1 in mediating the effects of AVC on COX-2 expression.

Main Methods:

  • A549 cells were exposed to hypoxia.
  • The effects of AVC on COX-2 protein levels and promoter activity were assessed.
  • The involvement of SIRT1 was examined using a SIRT1 inhibitor.

Main Results:

  • AVC suppressed the hypoxia-induced increase in COX-2 protein levels.
  • AVC reduced hypoxia-induced COX-2 promoter activity.
  • The inhibitory effects of AVC on COX-2 were reversed by a SIRT1 inhibitor, indicating SIRT1 mediation.

Conclusions:

  • Avenanthramide C inhibits hypoxia-induced COX-2 expression through SIRT1 activation.
  • AVC demonstrates potential as a therapeutic agent for preventing lung inflammation associated with hypoxia.

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K